Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Waters Introduces new UPLC Solution for Glycan Characterization
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Waters Corporation introduced the first UltraPerformance LC® (UPLC®) analytical solution for the characterization of 2-AB labeled glycans from glycoproteins. The UPLC solution combines new ACQUITY® UPLC BEH Glycan Columns with the ACQUITY UPLC System equipped with fluorescence detection.
Current FDA regulations require that firms developing and manufacturing therapeutic proteins are able to characterize the glycans attached to those proteins to ensure the efficacy and safety of a biopharmaceutical product.
Waters is introducing this solution at the request of scientists seeking to apply the power of UPLC technology to the development and analysis of glycans derived from therapeutic proteins.
“Customers were looking for improvements in LC resolution that would lead to more confident glycan identification and quantitation” said Mark Baynham, Director of Marketing, Chemistry Operations, Waters Division.
“With the introduction of our new UPLC BEH Glycan columns and ACQUITY UPLC Technology we have also responded to the increased pressure on their organizations for high throughput by providing UPLC benefits such as shortened analysis times without compromising their desired resolution.”
Initial customer feedback has shown the UPLC solution to be up to three times faster than traditional HPLC for the analysis of 2-aminobenzamide (2AB)-labeled glycans from human IgG.
In addition, to ensure confidence in long-term use in customer validated methods all ACQUITY UPLC BEH Glycan columns will be quality-control tested with relevant labeled glycan standards for consistent batch-to-batch column performance.
Expanding the Capabilities of UPLC Technology Waters ACQUITY UPLC BEH Glycan columns provide superior resolution for a wide range of glycans and represent the fifth application-tested UPLC column and eleventh UPLC chemistry added to the ever-expanding ACQUITY UPLC column family.
ACQUITY UPLC BEH Glycan columns are produced with the Waters Designed for Six Sigma (DFSS) Phase II ACQUITY UPLC column manufacturing process. This process produces long term performance by maximizing efficiency while minimizing column-to-column variability.
Current FDA regulations require that firms developing and manufacturing therapeutic proteins are able to characterize the glycans attached to those proteins to ensure the efficacy and safety of a biopharmaceutical product.
Waters is introducing this solution at the request of scientists seeking to apply the power of UPLC technology to the development and analysis of glycans derived from therapeutic proteins.
“Customers were looking for improvements in LC resolution that would lead to more confident glycan identification and quantitation” said Mark Baynham, Director of Marketing, Chemistry Operations, Waters Division.
“With the introduction of our new UPLC BEH Glycan columns and ACQUITY UPLC Technology we have also responded to the increased pressure on their organizations for high throughput by providing UPLC benefits such as shortened analysis times without compromising their desired resolution.”
Initial customer feedback has shown the UPLC solution to be up to three times faster than traditional HPLC for the analysis of 2-aminobenzamide (2AB)-labeled glycans from human IgG.
In addition, to ensure confidence in long-term use in customer validated methods all ACQUITY UPLC BEH Glycan columns will be quality-control tested with relevant labeled glycan standards for consistent batch-to-batch column performance.
Expanding the Capabilities of UPLC Technology Waters ACQUITY UPLC BEH Glycan columns provide superior resolution for a wide range of glycans and represent the fifth application-tested UPLC column and eleventh UPLC chemistry added to the ever-expanding ACQUITY UPLC column family.
ACQUITY UPLC BEH Glycan columns are produced with the Waters Designed for Six Sigma (DFSS) Phase II ACQUITY UPLC column manufacturing process. This process produces long term performance by maximizing efficiency while minimizing column-to-column variability.
